Doxorubicin induces protein ubiquitination and inhibits proteasome activity during cardiotoxicity

Toxicology

Volumn 309, Issue , 2013, Pages 23-29

  Sishi, Balindiwe J N ^a   Loos, Benjamin ^a   van Rooyen, Jacques ^b   Engelbrecht, Anna Mart ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

Author keywords

Cardiotoxicity; Doxorubicin; ER stress; Proteasome; Ubiquitin

Indexed keywords

DOXORUBICIN; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOBLAST; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE MARKER; DRUG BINDING; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEART CELL CULTURE; HEART MUSCLE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; UBIQUITIN PROTEASOME PATHWAY; UBIQUITINATION; UPREGULATION;

ANIMALS; CARDIOTOXINS; DOXORUBICIN; ENZYME ACTIVATION; FEMALE; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; RANDOM ALLOCATION; RATS; UBIQUITINATION;

EID: 84877896413     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.04.016     Document Type: Article

References (54)

1. Bodine S.C., Latres E., Baumheuter S., Lai V.K.M., Nunez L., Clarke B.A., Poueymirou W.T., Panaro F.J., Na E., Dharmarajan K., Pan Z.Q., Valenzuela D.M., DeChiara T.M., Stitt T.N., Yancopoulos G.D., Glass D.J. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708.
2. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 71:248-254.
3. Bulteau A.L., Lundberg K.C., Humphries K.M., Sadek H.A., Szweda P.A., Friguet B., Szweda L.I. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem. 2001, 276:30057-30063.
4. Cai D., Frantz J.D., Tawa N.E., Melendez P.A., Oh B.C., Lidov H.G., Hesselgren P.O., Frontera W.R., Lee J., Glass D.J., Shoelson S.E. IKKbeta/NFkappaB activation causes severe muscle wasting in mice. Cell 2004, 119:285-298.
5. Canu N., Barbato C., Ciotti M.T., Serafino A., Dus L., Calissano P. Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis. J. Neurosci. 2000, 20:589-599.
6. de Palma L., Marinelli M., Pavan M., Orazi A. Ubiquitin ligases MuRF1 and MAFbx in human skeletal muscle atrophy. Joint Bone Spine 2008, 75:53-57.
7. Dimitrakis P., Romay-Ogando M.I., Timolati F., Suter T.M., Zuppinger C. Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes. Cell Tissue Res. 2012, 350:361-372.
8. Ding W.-X., Ni H.-M., Gao W., Yoshimori T., Stolz D.-B., Ron D., Yin X.-M. Linking autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am. J. Pathol. 2007, 171:513-524.
9. Ewans A., Luo L., Berleth E., Alderfer J., Wollman R., Hafeez B.B., Kanter P., Mihich E., Ehrke M.J. Doxorubicin plus Interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res. 2006, 66:5419-5426.
10. Fekete M.R., McBride W.H., Pajonk F. Anthracyclines, proteasome activity and multi-drug-resistance. BMC Cancer 2005, 5:114-120.
11. Glass D.J. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat. Cell Biol. 2003, 5:87-90.
12. Glembotski C.C. Endoplasmic reticulum stress in the heart. Circulation 2007, 101:975-984.
13. Gruene T., Jung T., Merker K., Davies K.J. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and aggresomes during oxidative stress aging, and disease. Int. J. Biochem. Cell Biol. 2004, 36:2519-2530.
14. Harding H.P., Calfon M., Urano F., Novoa I., Ron D. Transcriptional and translational control in the mammalian unfolded protein response. Annu. Rev. Cell Dev. Biol. 2002, 18:575-599.
15. Herrmann J., Ciechanover A., Lerman L.O., Lerman A. The ubiquitin proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc. Res. 2004, 61:11-21.
16. Kaufman R.J. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev. 1999, 13:1211-1233.
17. Kedar V., McDonough H., Arya R., Li H.H., Rockman H.A., Patterson C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin 1. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:18135-18140.
18. Kiyomiya K., Kurebe M., Nakagawa H., Matsuo S. The role of the proteasome in apoptosis induced by anthracycline anticancer agents. Int. J. Oncol. 2002, 20:1205-1209.
19. Kiyomiya K., Matsuo S., Kurebe M. Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus. Life Sci. 1998, 62:1853-1860.
20. Kumarapeli A.R., Horak K.M., Glasford J.W., Li J., Chen Q., Liu J., Zheng H., Wang X. A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J. 2005, 19:2051-2053.
21. Lefrak E.A., Pitha J., Rosenheim S., Gottleib J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
22. Li Y., Chen Y., John J., Moylan J., Jin B., Mann D.L., Reid M.B. TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 2005, 19:362-370.
23. Lim C.C., Zuppinger C., Guo X., Kuster G.M., Helmes M., Eppenberger H.M., Suter T.M., Liao R., Sawyer D.B. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J. Biol. Chem. 2004, 279:8290-8299.
24. Liu J., Zheng H., Tang M., Ryu Y.-C., Wang X. A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2541-H2550.
25. Marambio P., Toro B., Sanhueza C., Troncoso R., Parra V., Verdejo H., Garcia L., Quiroga C., Munafo D., Diaz-Elizondo J., Bravo R., Gonzalez M.J., Diaz-Araya G., Pedrozo Z., Chiong M., Colombo M.I., Lavandero S. Glucose deprivation causes oxidative stress and stimulates aggresome formation and autophagy in cultured cardiac myocytes. Biochim. Biophys. Acta 2010, 1802:509-518.
26. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
27. Nalepa G., Rolfe M., Harper J.W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. 2006, 5:596-613.
28. Ogata M., Hino S., Saito A., Morikawa K., Kondo S., Kanemoto S., Murakami T., Taniguchi M., Tanii I., Yoshinaga K., Shiosaka S., Hammarback J.A., Urano F., Imaizumi K. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol. Cell. Biol. 2006, 26:9220-9231.
29. Orlowski M., Wilk S. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch. Biochem. Biophys. 2000, 383:1-16.
30. O'Shaughnessy J., Twelves C., Aapro M. Treatment for anthracycline-pretreated metastatic breast cancer. Oncologist 2002, 7:4-12.
31. Patterson C., Ike C., Willis IV P.W., Stouffer G.A., Willis M.S. The ubiquitin-proteasome system and cardiac dysfunction. Circulation 2007, 115:1456-1463.
32. Paul S. Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic conditions. Bioessays 2008, 30:1172-1184.
33. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 2001, 70:503-533.
34. Powell S.R. The ubiquitin-proteasome system in cardiac physiology and pathology. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1-H19.
35. Rao R.V., Ellerby H.M., Bredesen D.E. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ. 2004, 11:372-380.
36. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
37. Sardão V.A., Oliveira P.J., Holy J., Oliveira C.R., Wallace K.B. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear mitochondrial, and cytoskeletal targets. Cell Biol. Toxicol. 2009, 25:227-243.
38. Schimmel K.J.M., Richel D.J., van den Brink R.B.A., Guchelaar H.-J. Cardiotoxicity of cytotoxic drugs. Cancer Treat. Rev. 2004, 30:181-191.
39. Schröder M., Kaufman R.J. ER stress and the unfolded protein response. Mutat. Res. 2005, 569:29-63.
40. Sishi B.J.N., Bester D.J., Wergeland A., Loos B., Jonassen A.K., van Rooyen J., Engelbrecht A.-M. Daunorubicin therapy is associated with upregulation of E3 ubiquitin ligases in the heart. Exp. Biol. Med. 2012, 237:219-226.
41. Sishi B.J.N., Loos B., van Rooyen J., Engelbrecht A.-M. Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem. Pharmacol. 2013, 85:124-134.
42. Skurk C., Izumiya Y., Maatz H., Razeghi P., Shiojima I., Sandri M., Sato K., Zeng L., Schiekofer S., Pimentel D., Lecker S., Taegtmeyer H., Goldberg A.L., Walsh K. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J. Biol. Chem. 2005, 280:20814-20823.
43. Spence J., Sadis S., Haas A.L., Finley D. A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol. Cell. Biol. 1995, 15:1265-1273.
44. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
45. Timolati F., Anliker T., Groppalli V., Perriard J.C., Eppenberger H.M., Suter T.M., Zuppinger C. The role of cell death and myofibrillar damage in contractile dysfunction of long-term cultured cardiomyocytes exposed to doxorubicin. Cytotechnology 2009, 61:25-36.
46. Tran H., Brunet A., Griffith E.C., Greenberg M.E. The many forks in FOXO's road. Sci. STKE 2003, 2003:re5.
47. Von Huff D.D., Rozencweig M., Layar M., Slavik M., Muggia F.M. Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am. J. Med. 1977, 62:200-208.
48. Willis M.S., Patterson C. Into the heart: the emerging role of the ubiquitin-proteasome system. J. Mol. Cell. Cardiol. 2006, 41:567-579.
49. Witt S.H., Granzier H., Witt C.C., Labeit S. Murf-1 and Murf-2 target a specific subset of myofibrillar proteins redundantly: towards understanding Murf-dependent ubiquitination. J. Mol. Biol. 2005, 350:713-722.
50. Yamamoto Y., Hoshino Y., Ito T., Nariai T., Mohri T., Obana M., Hayata N., Uozumi Y., Maeda M., Fujio Y., Azuma J. Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc. Res. 2008, 79:89-96.
51. Zhang J., Clark J.R., Herman E.H., Ferrans V.J. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187. Am. J. Pathol. 1993, 142:1916-1926.
52. Zhao J., Brault J.J., Schild A., Cao P., Sandri M., Schiaffino S., Lecker S.H., Goldberg A.L. Fox-O3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007, 6:472-483.
53. Zheng Q., Li J., Wang X. Interplay between the ubiquitin-proteasome system and autophagy in proteinopathies. Int. J. Physiol. Pathophysiol. Pharmacol. 2009, 1:127-142.
54. Zhu W., Soonpa M.H., Chen H., Shen W., Payne R.M., Liechty E.A., Caldwell R.L., Shou W., Field L.J. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009, 119:99-106.